Blister Packaging Medication to Increase Treatment Adherence and Clinical Response
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/22/2017 |
| Start Date: | September 2009 |
| End Date: | September 2014 |
Blister Packaging Medication to Increase Treatment Adherence and Clinical Response: Impact on Suicide-Related Morbidity and Mortality
This quantitative, interview-based study will determine if increased prescription medication
adherence via blister pack administration will reduce suicide related behavior among the high
risk population of patients discharged from a psychiatric inpatient unit. The aims of the
project are to determine whether blister packaging medication significantly increases
treatment adherence and if blister packaging significantly decreases intentional
self-poisoning behavior (i.e., suicide attempts and completions). By tracking former
psychiatric inpatients for 12 months post-discharge and obtaining monthly medication
adherence ratings, we will determine if blister packaging (BP) medications leads to better
adherence than dispensing as usual (DUA). The psychiatric patients we will be recruiting have
been diagnosed with, major affective disorder, bipolar affective disorder, post-traumatic
stress disorder, or schizophrenia (or any combination of these diagnoses). By tracking former
psychiatric patients for 12 months post-discharge and obtaining monthly reports (self-report
and medical record review) of suicide-related behaviors, we will determine if patients in the
BP condition have less intentional self-poisoning behavior than those in the DAU condition.
adherence via blister pack administration will reduce suicide related behavior among the high
risk population of patients discharged from a psychiatric inpatient unit. The aims of the
project are to determine whether blister packaging medication significantly increases
treatment adherence and if blister packaging significantly decreases intentional
self-poisoning behavior (i.e., suicide attempts and completions). By tracking former
psychiatric inpatients for 12 months post-discharge and obtaining monthly medication
adherence ratings, we will determine if blister packaging (BP) medications leads to better
adherence than dispensing as usual (DUA). The psychiatric patients we will be recruiting have
been diagnosed with, major affective disorder, bipolar affective disorder, post-traumatic
stress disorder, or schizophrenia (or any combination of these diagnoses). By tracking former
psychiatric patients for 12 months post-discharge and obtaining monthly reports (self-report
and medical record review) of suicide-related behaviors, we will determine if patients in the
BP condition have less intentional self-poisoning behavior than those in the DAU condition.
Inclusion Criteria:
- age 18 or older
- diagnosed with major affective disorder,
- bipolar affective disorder,
- post-traumatic stress disorder, or
- schizophrenia (or any combination of these diagnoses)
- under voluntary status at some point during admission
- currently prescribed medications
- deemed capable of managing their own medications after discharge
- not currently active duty in any branch of the military
- able to correctly answer questions verifying they understand the consent form
- English-Speaking
Exclusion Criteria:
- Under the age of 18
- Not under voluntary status at some point during admission
- Not currently prescribed medications
- Not able to manage their own medications after discharge
- Non-English-speaking
- Currently active duty in any branch of the military
- Inability to correctly answer questions indicating comprehension of information on the
consent form
We found this trial at
1
site
Click here to add this to my saved trials
